Regulatory delays in bone marrow transplant approval
Government approval for bone marrow transplant unit is delayed due to procedural issues, pushing revenue contribution to FY28.
ASARFIHOSPITAL / bear-case history
Track the concerns that keep returning.
Asarfi Hospital · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Volatility in government scheme reimbursements
Changes in government scheme approval systems caused a decline in cancer patient volumes in Q4; future volatility could impact revenue.
Elevated receivables and working capital pressure
Receivables aging of 6-7 months due to delayed government reimbursements may keep working capital elevated.
Execution risk in aggressive growth targets
The FY27 revenue target of 260 crore and 500+ bed capacity by 2028 appear aggressive given current run-rate and regulatory hurdles.